Ultrasound Measurement of Reactive Hyperemia in Critical Care (URHC)

February 11, 2020 updated by: Anthony P. Pietropaoli, University of Rochester

Ultrasound Measurement of Reactive Hyperemia in Critical Care: Prognostic and Pathophysiologic Significance

The investigators hypothesize that doctors and nurses can undergo a brief period of training and then use ultrasound to accurately measure blood flow in a forearm artery after a brief period when this flow is interrupted with a blood pressure cuff, a measurement the investigators call reactive hyperemia. Reactive hyperemia indicates whether the small blood vessels in the body are healthy -- lower reactive hyperemia indicates worse small blood vessel function. When measured by experienced ultrasound experts, low reactive hyperemia strongly predicts death in critically ill patients with infection (severe sepsis).

The investigators are conducting this study to determine if doctors and nurses, without specific pre-existing expertise in ultrasound, can be trained to make these measurements accurately. If so, the investigators will prove that these measurements can be applied reliably in real-world practice.

The investigators also hypothesize that reactive hyperemia predict the outcomes of illness not just in patients with severe infection, but in other critically ill patients as well.

Finally, the investigators hypothesize that reduced blood flow after blood pressure cuff occlusion is linked with other abnormalities of blood, previously identified in critically ill patients. For example, red blood cells from patients with severe sepsis have been shown to be stiffer than normal, so they are less able to flow along the small blood vessel passages of the body. Red blood cells become stiffer when there is a certain type of stress in the body known as "oxidative stress."

If the investigators show that low reactive hyperemia, stiff red blood cells, and oxidative stress are linked, the investigators hope to develop new treatments that reduce oxidative stress, reduce the stiffness of red blood cells, and in turn improve reactive hyperemia. Improvements in reactive hyperemia indicate improvements in small blood vessel function. Better small blood vessel function means better delivery of oxygen throughout the body. The investigators believe that this will improve outcomes for critically ill patients.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Rochester, New York, United States, 14642
        • University of Rochester Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Critically ill Patients:

Patients admitted to University of Rochester Medical Center ICU services with 2 of the 4 systemic inflammatory response syndrome (SIRS) criteria and acute organ dysfunction will be considered for enrollment.

Healthy Control subjects:

Healthy control subjects >= 18 years of age will be recruited from the University and Rochester region at large.

Description

Inclusion Criteria:

  • Patients admitted to University of Rochester Medical Center ICU services with 2 of the 4 systemic inflammatory response syndrome (SIRS) criteria and acute organ dysfunction will be considered for enrollment.
  • Healthy control subjects >= 18 years of age will be recruited from the University and Rochester region at large.

Exclusion Criteria

  • Critically ill patients:

    1. Refusal of patient or designated surrogate decision-maker to provide written informed consent, or inability to obtain consent within 48 hours of diagnosis
    2. Attending physician refusal
    3. Hematocrit (Hct) < 21%
    4. Acute bleeding requiring PRBC transfusion
    5. History of chronic, dialysis dependent renal failure
    6. End-stage liver disease and Child-Pugh Grade C
    7. History of organ, bone marrow, or stem cell transplant
    8. Pregnancy
    9. Cardiac surgery (including ventricular assist device prior to first sample collection)
    10. Do not resuscitate at screening or plans for withdrawal of life support imminent
    11. Suicide attempt or intentional drug overdose;
    12. Jehovah's witness
  • Healthy Control subjects:

    1. Absent doppler signal in brachial or radial arteries.
    2. Asymmetric cyanosis, poor capillary refill or cold temperature
    3. Known venous thrombosis or there is asymmetric swelling (arm circumference > 2 inches larger than opposite side).
    4. Evidence of inflammation or impaired skin integrity of the involved limb.
    5. History of surgery involving the blood or lymphatic vessels of this limb, including axillary lymph node dissection, will preclude this testing.
    6. History of Anemia or G6PD deficiency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
severe sepsis
Patients with severe sepsis or septic shock
non-infected critically ill
Patients with severe non-infectious systemic inflammatory response syndrome
healthy
healthy volunteers

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
hospital mortality
Time Frame: vital status at hospital discharge, an expected average of 3 weeks
vital status at hospital discharge, an expected average of 3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Anthony P. Pietropaoli, M.D., M.P.H., University of Rochester

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2013

Primary Completion (ACTUAL)

December 1, 2019

Study Completion (ACTUAL)

December 1, 2019

Study Registration Dates

First Submitted

July 6, 2012

First Submitted That Met QC Criteria

November 10, 2012

First Posted (ESTIMATE)

November 15, 2012

Study Record Updates

Last Update Posted (ACTUAL)

February 12, 2020

Last Update Submitted That Met QC Criteria

February 11, 2020

Last Verified

February 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critical Illness

3
Subscribe